Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Chi, Kim N.; Higano, Celestia S.; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S.; Stenzl, Arnulf; Bergman, Andries M.; Mukherjee, Som D.; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S.

dc.contributor.author	Feyerabend, Susan
dc.contributor.author	Stenzl, Arnulf
dc.date.accessioned	2018-02-21T16:16:21Z
dc.date.available	2018-02-21T16:16:21Z
dc.date.issued	2017
dc.identifier.issn	1474-5488
dc.identifier.uri	http://hdl.handle.net/10900/80727
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(17)30168-7
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20170815222223_01349
utue.publikation.seiten	473-485	de_DE
utue.personen.roh	Chi, Kim N.
utue.personen.roh	Higano, Celestia S.
utue.personen.roh	Blumenstein, Brent
utue.personen.roh	Ferrero, Jean-Marc
utue.personen.roh	Reeves, James
utue.personen.roh	Feyerabend, Susan
utue.personen.roh	Gravis, Gwenaelle
utue.personen.roh	Merseburger, Axel S.
utue.personen.roh	Stenzl, Arnulf
utue.personen.roh	Bergman, Andries M.
utue.personen.roh	Mukherjee, Som D.
utue.personen.roh	Zalewski, Pawel
utue.personen.roh	Saad, Fred
utue.personen.roh	Jacobs, Cindy
utue.personen.roh	Gleave, Martin
utue.personen.roh	de Bono, Johann S.
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	4	de_DE
dcterms.isPartOf.ZS-Volume	18	de_DE
utue.fakultaet	04 Medizinische Fakultät
utue.fakultaet	Universität Tübingen (ohne Fakultätsangabe)